{
  "id": 20452299,
  "title": "SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,",
  "url": "https://urgent.news/2026/11/17/sellas-stock-triples-on-cancer-vaccine-cutting-death-risk-by-41-in",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-17T15:09:46.000Z",
  "source": {
    "name": "Benzinga",
    "slug": "benzinga",
    "url": "https://www.benzinga.com/trading-ideas/movers/26/11/63344384/sellas-stock-triples-on-cancer-vaccine-cutting-death-risk-by-41-in-pivotal-leukemia-trial"
  },
  "original_language": "en",
  "account": "SELLAS Life Sciences Group Inc. (NASDAQ:SLS) shares surged to a 52-week high as positive results from a pivotal Phase 3 leukemia trial were announced. The company confirmed that its cancer vaccine, galinpepimut-S (GPS), met its primary endpoint of overall survival in the trial. GPS reduced the risk of death by 41% compared to the best available treatment. The late-stage biopharmaceutical company licensed GPS from Memorial Sloan Kettering Cancer Center as an off-the-shelf vaccine targeting a protein expressed across multiple blood cancers and solid tumors. SLS stock is now trading at a new 52-week high of $21.14.",
  "summary": "SELLAS Life Sciences Group Inc. (NASDAQ:SLS) skyrocketed to a 52-week high on Tuesday with a session volume of a massive 57.567 million compared to an average volume of 6.897 million, according to Benzinga Pro data . The company released positive topline results from its pivotal randomized Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine for acute myeloid…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}